These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39206786)

  • 1. Brief Communication: Treatment Outcomes for Advanced Melanoma of Unknown Primary Compared With Melanoma With Known Primary.
    Persa OD; Hassel JC; Steeb T; Erdmann M; Karimi B; Stege H; Klespe KC; Schatton K; Tomsitz D; Rübben A; Thiem A; Berking C; Biedermann T
    J Immunother; 2024 Nov-Dec 01; 47(9):384-387. PubMed ID: 39206786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis.
    Ludwig SV; F Cheng P; Mangana J; Braun R; Dummer R; Koelblinger P
    Eur J Dermatol; 2020 Dec; 30(6):699-709. PubMed ID: 33459260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.
    Verver D; Grünhagen DJ; van Akkooi ACJ; Aarts MJB; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; Boers-Sonderen MJ; Haanen JBAG; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Tije AJT; Vreugdenhil G; Verhoef C; van der Veldt AAM
    Cancer Immunol Immunother; 2021 Nov; 70(11):3123-3135. PubMed ID: 33774697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival for stage IV melanoma from an unknown primary site.
    Lee CC; Faries MB; Wanek LA; Morton DL
    J Clin Oncol; 2009 Jul; 27(21):3489-95. PubMed ID: 19451446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma of unknown primary: New perspectives for an old story.
    Boussios S; Rassy E; Samartzis E; Moschetta M; Sheriff M; Pérez-Fidalgo JA; Pavlidis N
    Crit Rev Oncol Hematol; 2021 Feb; 158():103208. PubMed ID: 33383207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma.
    Lee CC; Faries MB; Wanek LA; Morton DL
    J Clin Oncol; 2008 Feb; 26(4):535-41. PubMed ID: 18235114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.
    Utter K; Goldman C; Weiss SA; Shapiro RL; Berman RS; Wilson MA; Pavlick AC; Osman I
    Oncology; 2017; 93(4):249-258. PubMed ID: 28746931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results.
    Gambichler T; Chatzipantazi M; Schröter U; Stockfleth E; Gedik C
    Oncoimmunology; 2019; 8(12):e1677139. PubMed ID: 31741779
    [No Abstract]   [Full Text] [Related]  

  • 9. Melanoma of unknown primary origin: a population-based study in the Netherlands.
    de Waal AC; Aben KK; van Rossum MM; Kiemeney LA
    Eur J Cancer; 2013 Feb; 49(3):676-83. PubMed ID: 23031553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study.
    Verver D; van der Veldt A; van Akkooi A; Verhoef C; Grünhagen DJ; Louwman WJ
    Int J Cancer; 2020 Jan; 146(1):26-34. PubMed ID: 30801710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease.
    van der Ploeg AP; Haydu LE; Spillane AJ; Scolyer RA; Quinn MJ; Saw RP; Shannon KF; Stretch JR; Thompson JF
    Ann Surg Oncol; 2014 Sep; 21(9):3108-16. PubMed ID: 24802907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study.
    Del Fiore P; Rastrelli M; Dall'Olmo L; Cavallin F; Cappellesso R; Vecchiato A; Buja A; Spina R; Parisi A; Mazzarotto R; Ferrazzi B; Grego A; Rotondi A; Benna C; Tropea S; Russano F; Filoni A; Bassetto F; Tos APD; Alaibac M; Rossi CR; Pigozzo J; Sileni VC; Mocellin S
    Front Oncol; 2021; 11():627527. PubMed ID: 33747946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014.
    Scott JF; Conic RZ; Thompson CL; Gerstenblith MR; Bordeaux JS
    J Am Acad Dermatol; 2018 Aug; 79(2):258-265.e4. PubMed ID: 29580859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival after lymphadenectomy of nodal metastases from melanoma of unknown primary site.
    Gullestad HP; Ryder T; Goscinski M
    J Plast Surg Hand Surg; 2023; 57(1-6):109-114. PubMed ID: 34878354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site.
    Prens SP; van der Ploeg AP; van Akkooi AC; van Montfort CA; van Geel AN; de Wilt JH; Eggermont AM; Verhoef C
    Ann Surg Oncol; 2011 Dec; 18(13):3586-92. PubMed ID: 21611857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling.
    De Andrade JP; Wong P; O'Leary MP; Parekh V; Amini A; Schoellhammer HF; Margolin KA; Afkhami M; Melstrom LG
    Ann Surg Oncol; 2020 Dec; 27(13):5240-5247. PubMed ID: 32909128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome.
    Hughes MC; Wright A; Barbour A; Thomas J; Smithers BM; Green AC; Khosrotehrani K
    Int J Cancer; 2013 Dec; 133(12):3000-7. PubMed ID: 23754707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.